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Results From November 2010 to March 2012, 882 
patients were enrolled at 198 institutions. Safety was 
analyzed in 828 patients with finalized data out of 
848 patients receiving mFOLFOX6. The incidence 
of PSN persisting ≥8 days was 3.3 % [95 % confi-
dence interval (CI) 2.2–4.7], while that of grade 3–4 
AR was 1.7 % (95 % CI 0.9–2.8). The treatment com-
pletion rate was 67.0 %. The median total dosage of 
oxaliplatin was 811.1 mg/m2. The overall incidence 
of grade 3–4 PSN was 5.8 %. Interstitial pneumoni-
tis occurred in one patient. There were no treatment-
related deaths.
Conclusions Adjuvant mFOLFOX6 is tolerable for Japa-
nese patients with colon cancer.
Keywords Colon cancer · mFOLFOX6 · Adjuvant · 
Peripheral sensory neuropathy · Allergic reactions
Abstract 
Purpose Adjuvant FOLFOX is a widely accepted stand-
ard therapy for resected colon cancer. The incidence of 
grade 3–4 peripheral sensory neuropathy (PSN) was 12.4 
and 5.7 % in the MOSAIC and Eastern MASCOT trials, 
while that of grade 3–4 allergic reactions (AR) was 2.9 
and 3.1 %, respectively. The JFMC41-1001-C2 trial (JOIN 
trial) investigated the tolerability of modified FOLFOX6 
(mFOLFOX6) in Japanese colon cancer patients.
Methods Twelve cycles of mFOLFOX6 were given to 
patients with the same eligibility criteria as in the MOSAIC 
study: stage II or III curatively resected colon cancer, per-
formance status of 0–1, aged 20 years or older, starting 
mFOLFOX6 within 7 weeks of surgery, and adequate organ 
function. The primary endpoints were the incidence of PSN 
persisting for ≥8 days that interfered with daily activities 
and the incidence of grade 3–4 AR. The target sample size 
was 800.
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Introduction
FOLFOX is the combination of 5-fluorouracil (5-FU) and 
l-leucovorin (1-LV) with oxaliplatin (L-OHP) and is rec-
ommended as one of the standard adjuvant chemotherapy 
regimens for patients with curatively resected colon cancer 
by the National Comprehensive Cancer Network (NCCN) 
guidelines [1]. In Japan, it is also recommended by the 
2010 Guidelines for the Treatment of Colorectal Cancer of 
the Japanese Society for Cancer of the Colon and Rectum 
(JSCCR) [2]. Adjuvant FOLFOX is indicated for patients 
who have stage III colon cancer with lymph node metasta-
sis, as well as for patients with high-risk stage II colon can-
cer who have risk factors for recurrence that are known to 
be associated with a relatively poor prognosis, such as T4 
status, poorly differentiated histology, vascular invasion, 
ileus, <12 lymph nodes examined, and neural invasion [1].
The MOSAIC trial was a large-scale randomized con-
trolled trial performed mainly in Europe that assessed 
the efficacy and safety of FOLFOX4 as adjuvant therapy 
[3, 4]. Significant improvement in disease-free survival 
(DFS) and overall survival (OS) was seen in the FOL-
FOX4 group compared with the LV5FU2 group (receiv-
ing 1-LV modulated infusional 5-FU therapy). In addition, 
the NSABP C-08 trial confirmed that modified FOLFOX6 
(mFOLFOX6) therapy was equivalent to FOLFOX4 ther-
apy in terms of efficacy and safety [5, 6].
Either adjuvant FOLFOX4 or mFOLFOX6 is routinely 
given as 12 courses (2 weeks per course). However, con-
tinuation of treatment is often interrupted/discontinued 
by the development of severe peripheral sensory neuropa-
thy (PSN) and allergic reactions/anaphylaxis (AR). In the 
MOSAIC trial, the incidence of grade ≥1 PSN and grade 
≥1 AR due to FOLFOX4 therapy was 92.0 and 10.3 %, 
respectively, while grade ≥3 PSN and grade ≥3 AR had 
an incidence of 12.4 and 2.9 %, respectively [3, 4]. In the 
MASCOT trial, which was conducted to confirm the safety 
of FOLFOX4 therapy in Asian countries other than Japan 
(China, Hong Kong, South Korea, Taiwan, and Thailand), 
the incidence of grade ≥1 PSN and grade ≥1 AR was 86.2 
and 25.2 %, respectively, while grade ≥3 reactions showed 
an incidence of 5.7 and 3.1 %, respectively: The incidence 
of grade ≥3 PSN and grade ≥1AR differed between the 
two trials [7].
In the NSABP C-08 trial, adjuvant mFOLFOX6 therapy 
caused grade ≥3 PSN and grade ≥3 AR at an incidence 
of 14.4 and 4.7 %, respectively [5], but to our knowledge, 
the incidence of grade ≥1 PSN and grade ≥1 AR has not 
been reported yet. In addition, there are no safety data for 
adjuvant mFOLFOX6 therapy in the Asian population. 
Therefore, we conducted the present study (JFMC41-
1001-C2; JOIN trial) to confirm the tolerability of adju-
vant mFOLFOX6 therapy in Japanese patients (UMIN ID: 




Eligibility criteria for this study corresponded to those for 
the MOSAIC trial and were as follows: a pathological stage 
II (T3-4N0M0) or stage III (TanyN1-2M0) colon cancer 
[8] (including cancer of the rectosigmoid region); curative 
resection (curative level A) and no macroscopic and micro-
scopic residual tumors; starting mFOLFOX6 therapy within 
7 weeks after surgery and within 2 weeks after enrollment; 
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 0–1; an age of 20 years or older; no 
prior chemotherapy, immunotherapy, or radiation therapy; 
adequate function of vital organs [neutrophil count ≥1500/
mm3, platelet count ≥100,000/mm3, serum creatinine 
≤1.25× institutional upper limit of normal (ULN)]; total 
bilirubin <2× ULN, aspartate aminotransferase and alanine 
aminotransferase <2× ULN, and carcinoembryonic antigen 
<10 ng/mL; no serious complications; and providing writ-
ten informed consent before enrollment. The study protocol 
was approved in all participating institutions.
Study treatment and dose modification
The study treatment was mFOLFOX6 therapy (L-OHP, 
85 mg/m2; 1-LV, 200 mg/m2; 5-FU bolus, 400 mg/m2; and 
5-FU infusion, 2400 mg/m2),with a total of 12 courses 
being administered at 2-week intervals. Further chemother-
apy was not performed until recurrence after completion of 
the scheduled therapy.
If the following criteria for initiation of treatment 
were not met on the day of or the day before the start of 
each course, treatment was postponed for a maximum of 
29 days: neutrophil count ≥1500/mm3, platelet count 
≥75,000/mm3, and other parameters at the attending physi-
cian’s discretion. If adverse events of a high enough grade 
occurred during the previous course, the dose was reduced 
by 1 level (up to 2 levels). Bolus 5-FU was discontin-
ued after dose reduction by 1 level, but the dose of 1-LV 
was not reduced. If any of the following adverse events 
occurred (except PSN), the doses of L-OHP and infusional 
5-FU were, respectively, reduced to 75 or 55 mg/m2 and 
1900 or 1400 mg/m2: grade ≥3 (or persistent grade 2 for 
2 weeks) neutropenia or thrombocytopenia and any other 
grade 3 non-hematological drug-related adverse events. 
Infusional 5-FU was reduced to 1900 or 1400 mg/m2 if 
any of the following adverse events occurred: grade 3 (or 
persistent grade 2 for 2 weeks) diarrhea, oral mucositis, or 
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skin disorders. Study treatment was discontinued if any of 
the following adverse events occurred: grade 4 diarrhea, 
oral mucositis, or skin disorders, and other grade 4 non-
hematological drug-related adverse events. L-OHP was dis-
continued if grade ≥3 AR occurred.
The dose of L-OHP was reduced to 75 or 55 mg/m2 if 
the patient developed persistent painless PSN for ≥14 days, 
painful PSN for 8–13 days, or PSN with dysfunction for 
≤7 days. The dose of L-OHP was reduced to 55 mg/m2 if 
the patient developed persistent painful PSN for ≥14 days 
or PSN with dysfunction for 8–13 days. L-OHP was dis-
continued if the patient developed persistent PSN with 
dysfunction for ≥14 days or PSN with dysfunction for 
8–13 days following painful PSN for ≥14 days.
Primary and secondary endpoints
The primary endpoints were the incidence of PSN persisting 
for ≥8 days that interfered with daily activities and the inci-
dence of grade ≥3 AR. Secondary endpoints were disease-
free survival (DFS), relapse-free survival, time to treatment 
failure, overall survival (OS), adverse events (AEs) includ-
ing any grade of PSN or AR, comparison of PSN between 
patients receiving prophylactic therapy with IV calcium/
magnesium and/or oral goshajinkigan, etc., at the physi-
cian’s discretion and patients not receiving such prophy-
lactic therapy, recovery of PSN during the 3-year follow-
up period, the treatment completion rate, the relative dose 
intensity (RDI), and the number of lymph node metastases, 
and number of dissected lymph nodes in relation to the 
prognosis. For prophylactic IV calcium/magnesium, gos-
hajinkigan, and IV calcium/magnesium plus goshajinkigan, 
cases of concomitant use in the first course were counted.
AEs were evaluated according to the Common Termi-
nology Criteria for Adverse Events (CTCAE) Version 4.0. 
However, PSN was evaluated by following the NCI-CTC 
Version 1.0, 2.0 and CTCAE Version 3.0. Dose intensity 
was calculated as the total dose divided by the duration of 
dosing, while the planned dose intensity was calculated as 
the planned dose divided by 14. Then RDI was calculated 
as dose intensity/planned dose intensity ×100.
Enrollment and data collection
An electronic data capture system (Viedoc®, PCG Solu-
tions, Uppsala, Sweden) was used for registration of the 
subjects and collection of data related to the endpoints 
for each patient. Central monitoring was performed, and 
further information was obtained from the attending phy-
sicians as required to confirm the accuracy of the data by 
each query. The expected enrollment period was 3 years, 
with an additional follow-up period of 3 years after enroll-
ment of the last patients.
Sample size and statistical analysis
Assuming that the incidence of grade ≥3 PSN is 12.0 % 
(threshold incidence: 16.5 %) and the incidence of grade 
≥3 AR is 3.0 % (threshold incidence: 6.5 %), based on the 
results of the MOSAIC trial, when the probability that a 
two-sided 95 % confidence interval (CI) for the incidence 
of each adverse event does not contain the threshold inci-
dence is set as 95 %, the number of patients required to 
evaluate grade ≥3 PSN and AR was calculated to be 798 
and 510, respectively. The 95 % CI was calculated by the 
adjusted Wald-based method [9]. Accordingly, a target of 
800 patients was set for enrollment.
Fig. 1  CONSORT diagram
Table 1  Profile of the subjects
a General Rules for Clinical and Pathological Studies on Cancer of 
the Colon, Rectum, and Anus, 7th edition, revised
b TNM Classification of Malignant Tumours, 7th edition
828
Male/female 444/384
Median age (range) 64 (21–83)
Performance status 0/1 776/52
Colon/Rectosigmoid 633/195
Stagea II/IIIa/IIIb 152/402/274
Stage (TNM 7th)b IIA/IIB/IIC/IIIA/IIIB/IIIC 96/33/23/61/437/178
N0/N1/N2/N3a 152/402/225/49
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The incidence of grade ≥3 PSN and grade ≥3 AR was cal-
culated as percentages with the adjusted Wald-based 95 % CI. 
If the upper limit of the 95 % CI did not include the thresh-
old incidence, it was concluded that adjuvant mFOLFOX6 
therapy was as tolerable for Japanese patients as for Western 
patients. The Kaplan–Meier method was used to evaluate the 
relationship between the total dose and the cumulative inci-
dence of PSN or AR. If a drug administration was stopped, 
data were censored at that point. The median total dose was 
estimated from the cumulative incidence curve, and the 95 % 
CI was estimated by the Greenwood formula. In the pre-spec-
ified sub-analysis, the influence of prophylactic treatment and 
other variables on occurrence of grade ≥2 PSN was evaluated 
in univariate and multivariate logistic regression analysis. 
Variables evaluated in the model were age, sex, performance 
status, stage, total dose of L-OHP, and prophylactic pretreat-
ment. SAS Release 9.3 (SAS Institute, Cary, NC, USA) was 
used for all statistical analyses.
Results
Profile of the subjects
Between November 2010 and March 2012 (17 months), 
882 patients were enrolled at 198 institutions. Among these 
Fig. 2  The incidence of PSN 
and AR
Fig. 3  The cumulative inci-
dence of PSN (grade ≥1/grade 
≥2/grade 3)
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882 patients, 11 were ineligible, 9 did not start the study 
treatment, and 14 did not receive the correct initial dos-
age at their physician’s discretion. These 34 patients were 
excluded from the safety analysis by central monitoring. 
Of the remaining 848 patients, 828 patients for whom the 
treatment status was fixed by April 30, 2013, were included 
in the safety analysis (Fig. 1). The characteristics of these 
patients are shown in Table 1.
Primary endpoints
The incidence of PSN persisting for ≥8 days that interfered 
with daily activities and the incidence of grade ≥3 AR were 
3.3 % (95 % CI 2.2–4.7) and 1.7 % (95 % CI 1.0–2.8), 
respectively. At the onset of PSN persisting for ≥8 days 
that interfered with daily activities, the median total dose of 
L-OHP and the median number of courses were 672.5 mg/
m2 and 9, respectively, while the corresponding values were 
565.1 mg/m2 and 7.5 at the onset of grade ≥3 AR.
Treatment
The median number of courses was 12 (range: 1–12), and 
the treatment completion rate was 67.0 %. The median 
total doses of L-OHP, bolus 5-FU, and infusional 5-FU 
were 811.1 mg/m2, 2798.3 mg/m2, and 24,009.0 mg/m2, 
Fig. 4  PSN: the incidence of 
each course (grade 1/grade 2/
grade 3)
Fig. 5  AR: the incidence of 
each course (grade 1 and 2/
grade 3)
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respectively, while the median RDI was 78.2, 87.7, and 
78.1 %, respectively.
Incidence of PSN and AR
The incidence of grade ≥1 PSN was 83.8 %, and the inci-
dence of grade ≥3 PSN was 5.8 %, while the respective 
values for AR were 14.3 and 1.7 % (Fig. 2). The cumula-
tive incidence of each grade of PSN increased along with 
the total dose of L-OHP (Fig. 3). While the incidence of 
grade 1 PSN showed little change after the fourth course, 
grade 2–3 PSN tended to increase with the course number 
(Fig. 4). AR was observed from the first course, although 
its incidence particularly increased after the sixth course 
(Fig. 5).
Pre‑specified sub‑analysis: effect of prophylactic 
treatment for PSN
Univariate analysis of the factors related to grade ≥2 PSN 
is shown in Table 2. In addition to a total dose of L-OHP 
≥510 mg/m2, there was a significant difference in relation 
to the use of calcium/magnesium and use of goshajinkigan 
as prophylactic treatment at the initial course of mFOL-
FOX6, showing the likelihood of detrimental effects on 
grade ≥2 PSN. Table 3 shows the results of the multivariate 
analysis of factors related to the occurrence of grade ≥2 
PSN, with a significant difference being observed only for 
a total L-OHP dose of ≥510 mg/m2. The odds ratios for 
prophylactic monotherapy with calcium/magnesium, mon-
otherapy with goshajinkigan, and concomitant therapy with 
both agents were 1.345, 1.624, and 2.184, respectively.
Adverse events
The AEs that occurred during this study are shown in 
Table 4. The only grade ≥3 AE occurring in more than 
10 % of the patients was neutropenia, which was observed 
in 28.7 %. However, the incidence of febrile neutropenia 
was 0.4 %. There was only one case of grade 3 interstitial 
pneumonitis, and there were no treatment-related deaths.
Discussion
To our knowledge, this is the first large-scale study of PSN 
persisting for ≥8 days that interfered with daily activi-
ties and grade ≥3 AR in Asian patients receiving mFOL-
FOX6 as adjuvant chemotherapy after curative resection 
of stage II or III colon cancer. The incidence of persistent 
PSN was 3.3 % (95 % CI 2.2–4.7), while that of grade ≥3 
AR was 1.7 % (95 % CI 1.0–2.8). Since the upper limit of 
Table 2  Relationship of 
variables with the onset of PSN 
of grade ≥2: univariate analysis
For prophylactic Ca/Mg and goshajinkigan, cases of concomitant use in the first course were counted
Explanatory variables Logistic regression analysis
n Odds ratio
Point estimate




 <70 years old 588 1.000 – –
 ≥70 years old 240 0.794 0.579–1.090 0.1539
Sex
 Male 444 1.000 – –
 Female 384 1.256 0.946–1.669 0.1153
Performance status
 0 776 1.000 – –
 1 52 1.314 0.743–2.321 0.3477
Stage
 II 152 1.000 – –
 III 676 1.114 0.770–1.613 0.5662
Total dose of L-OHP
 <510 mg/m2 158 1.000 – –
 ≥510 mg/m2 670 2.113 1.417–3.151 <0.001
Prophylactic pretreatment
 Without Ca/Mg 696 1.000 – –
 With Ca/Mg 132 1.583 1.087–2.307 0.0168
 Without goshajinkigan 733 1.000 – –
 With goshajinkigan 95 2.045 1.330–3.145 0.0011
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the 95 % CI of the incidence of each event (PSN: 4.7 %; 
AR: 2.8 %) was lower than the threshold incidence (PSN: 
16.5 %; AR: 6.5 %), the primary endpoint was met and we 
confirmed that both persistent PSN and grade ≥3 AR were 
not statistically more frequent than the reported incidences 
in Western patients during the MOSAIC and NSABP C-08 
trials.
We selected mFOLFOX6 as the regimen for this study 
because it is more simple and easier than FOLFOX4 in 
terms of administration procedure. mFOLFOX6 is widely 
used around the world (for example, it was the reference 
regimen in the NSABP C-08 study [5, 6]) because a cross-
sectional comparison of these two regimens for advanced 
and/or recurrent colorectal cancer showed comparable effi-
cacy and safety [10].
Table 5 displays a comparison of the present findings with 
the results of the MOSAIC [3], MASCOT [7], and NSABP 
C-08 [5] trials regarding safety and administration. In the 
present study, the incidence of grade ≥3 PSN was 5.8 % 
(3.3 % for PSN persisting for ≥8 days that interfered with 
daily activities), which was lower than the incidence in the 
MOSAIC trial (12.4 %) and the NSABP C-08 trial (14.4 %), 
and comparable with that in the MASCOT trial (5.7 %). The 
incidence of grade ≥3 AR was 1.7 % in this study, which 
was lower than in the MOSAIC (2.9 %), MASCOT (3.1 %), 
or NSABP C-08 (4.7 %) trials. Comparison between this 
study and the MOSAIC trial showed that the median course 
number was 12 in both, while the cumulative treatment 
Table 3  Relationship of 
variables with the onset of 
PSN of grade ≥2: Multivariate 
analysis
For prophylactic Ca/Mg, goshajinkigan, and Ca/Mg plus goshajinkigan, cases of concomitant use in the 
first course were counted
Explanatory variables Logistic regression analysis
n Odds ratio
Point estimate




 <70 years old 1.000 – –
 ≥70 years old 0.780 0.562–1.083 0.1377
Sex
 Male 1.000 – –
 Female 1.266 0.944–1.697 0.1155
Performance status
 0 1.000 – –
 1 1.287 0.714–2.319 0.4021
Stage
 II 1.000 – –
 III 0.999 0.683–1.461 0.9944
Total dose of L-OHP
 <510 mg/m2 1.000 – –
 ≥510 mg/m2 2.132 1.420–3.201 <0.001
Prophylactic pretreatment
 No prior treatment 627 1.000 – –
 Ca/Mg (monotherapy) 106 1.345 0.808–2.238 0.2573
 Goshajinkigan (monotherapy) 69 1.624 0.977–2.699 0.0612
 Ca/Mg + goshajinkigan  
(concomitant therapy)
26 2.184 0.975–4.895 0.0577
Table 4  Adverse events
CTCAE version 4.0
n (%)
Grade ≥1 Grade ≥3
Neutropenia 441 (53.3 %) 238 (28.7 %)
Leucopenia 265 (32.0 %) 21 (2.5 %)
Thrombocytopenia 264 (31.9 %) 14 (1.7 %)
Diarrhea 153 (18.5 %) 17 (2.1 %)
Anorexia 255 (30.8 %) 17 (2.1 %)
Nausea 311 (37.6 %) 14 (1.7 %)
ALT (GPT) increased 199 (24.0 %) 13 (1.6 %)
Fatigue 205 (24.8 %) 10 (1.2 %)
Vomiting 90 (10.9 %) 6 (0.7 %)
AST (GOT) increased 211 (25.5 %) 5 (0.6 %)
Febrile neutropenia 3 (0.4 %) 3 (0.4 %)
Pneumonitis (interstitial pneumonitis) 7 (0.8 %) 1 (0.1 %)
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completion rate was 67.0 % and 74.7 %, the median total 
dose of L-OHP was 811.1 and 810.0 mg/m2, and the median 
RDI for L-OHP was 78.2 and 80.5 %, respectively. In rela-
tion to tolerability, it is worth noting that the administration 
of therapy was similar in both studies, but the incidence of 
grade ≥3 PSN and grade ≥3 AR was lower in the present 
study. This was probably because it was possible to reduce 
the L-OHP dose by up to two levels in the present study 
depending on the severity and duration of PSN.
The sub-analysis did not demonstrate efficacy of pro-
phylactic treatment for PSN. In a previous phase III clinical 
study [11], calcium/magnesium adjuvant therapy did not 
show efficacy against PSN induced by L-OHP and the pre-
sent findings were consistent with that report. In a previous 
phase II randomized controlled study performed in patients 
with advanced/recurrent colorectal cancer, the Kampo 
medicine goshajinkigan was reported to be effective against 
PSN induced by FOLFOX4 therapy or mFOLFOX6 ther-
apy [12]. However, our multivariate analysis showed that 
prophylactic monotherapy with calcium/magnesium, gos-
hajinkigan, or concomitant therapy with calcium/mag-
nesium and goshajinkigan did not prevent the develop-
ment of grade ≥2 PSN [hazard ratio (HR) 1.345, 95 % CI 
0.808–2.238; HR 1.624, 95 % CI 0.977–2.699; HR 2.184, 
95 % CI 0.975–4.895, respectively]. Similar to our study, a 
phase III randomized double-blind clinical study was con-
ducted using goshajinkigan as adjuvant therapy [13]. At the 
interim analysis, efficacy for PSN induced by mFOLFOX6 
therapy was not demonstrated and the study was terminated 
prematurely. In our study, prophylactic treatment with cal-
cium/magnesium or goshajinkigan was selected at the dis-
cretion of the attending physician. Therefore, we must be 
cautious about potential bias as a result of non-randomized 
selection of patients among specific study sites and detailed 
explanations to patients about PSN from the investigator. 
Also, a relatively small number of patients on prophylactic 
treatment were studied, although our current results were 
obtained from a pre-specified sub-analysis. However, there 
have been no other reports about prophylactic treatment 
with concomitant calcium/magnesium and goshajinkigan. 
We found that even combining both agents did not have a 
preventive effect against PSN induced by L-OHP. If a pro-
spective investigation of prophylaxis for PSN is conducted 
in the future, our current findings should be taken into con-
siderations when developing the study design.
The incidence of grade ≥3 neutropenia was 28.7 % in 
this study, which was lower than in the MOSAIC (41.0 %) 
and MASCOT (52.2 %) trials. This was probably related to 
the difference in the number of bolus 5-FU doses between 
mFOLFOX6 therapy used in the present study and FOL-
FOX4 therapy used in the MOSAIC and MASCOT trials. 
In the NSABP C-08 study [5], mFOLFOX6 was adminis-
tered as adjuvant chemotherapy to patients with curatively 
resected stage II or III colon cancer and the incidence of 
grade ≥3 neutropenia was 32.6 %, which was comparable 
with that in the present study.
Among the 828 patients analyzed in this study, about 
20 % had stage II disease, about 60 % were in stage IIIA or 
IIIB, and about 20 % were in stage IIIC. The clinical use-
fulness of adjuvant chemotherapy for stage II colon cancer 
remains controversial because some reports have supported 
its efficacy [14–18] and others have not [19, 20]. Therefore, 
it is interesting that stage II patients accounted for approxi-
mately 20 % of our subjects. This may be because explora-
tory analysis of 569 patients with stage II colon cancer from 
the MOSAIC trial [4] (282 in the FOLFOX4 group and 287 
in the LV5FU2 group) who had risk factors for recurrence 
(one or more of T4, tumor perforation, bowel obstruction, 
undifferentiated tumor, vascular invasion, or < 10 lymph 
nodes examined) showed that DFS at 5 years was better in 
the FOLFOX4 group than in the LV5FU2 group [82.1 vs. 
74.9 %, HR 0.74 (95 % CI 0.52–1.06)].
Table 5  Comparison among the JOIN, MOSAIC, MASCOT, and NSABP C-08 trials
a Calculated from the dose intensity described in the report
b PSN persisting for at least 8 days that interfered with daily activities
c Based on the data for 1.108 subjects
d Based on the data for 1321 subjects
JOIN (n = 828) MOSAIC (n = 1123) MASCOT (n = 159) NSABP C-08 (n = 1350)
Median number of courses 12 12 12 –
Treatment completion rate (%) 67.0 74.7 81.8 –
Median total dose of L-OHP (mg/m2) 811.1 810.0 – 850.0
Median RDI of L-OHP (%) 78.2 80.5 84.0a 95.4
Adverse events (grade ≥ 3)
 Neutropenia (%) 28.7 41.0c 52.2 32.6d
 PSN (%) 5.8 (3.3b) 12.4c 5.7 14.4d
 AR (%) 1.7 2.9c 3.1 4.7d
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The median age of the 828 patients analyzed in our 
study was 64 years, and 240 patients were aged 70 years 
or older (29.0 %). In contrast, the eligibility criteria of 
the MOSAIC trial included an age under 76 years, and 
only 315 out of 2246 patients were aged 70 years or older 
(14.0 %) [21]. Presumably, patients aged 70 years or older 
accounted for 29.0 % of the present study population 
because an upper age limit was not set in the eligibility 
criteria and because the JSCCR Guidelines 2010 for the 
Treatment of Colorectal Cancer [2] also recommend adju-
vant chemotherapy for elderly patients aged ≥70 years, 
depending on their PS and organ function. Results for the 
secondary endpoints (efficacy including DFS and the long-
term outcome of PSN) are not reported here and will be 
reported in the future.
Currently, the International Duration Evaluation of 
Adjuvant Chemotherapy (IDEA) collaboration is inves-
tigating whether the duration of L-OHP-based adjuvant 
chemotherapy can be reduced from 6 to 3 months while 
maintaining efficacy, and pooled analysis will be per-
formed using data from multiple large-scale clinical stud-
ies that are ongoing around the world [22]. In Japan, the 
JFMC47-1202-C3 study of stage III colon cancer and the 
JFMC48-1301-C4 study of stage II colon cancer with risk 
factors for recurrence are participating in IDEA.
In conclusion, this study showed that adjuvant mFOL-
FOX6 therapy is tolerated in Japanese patients with cura-
tively resected stage II or III colon cancer.
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